[18F]MNI-958
- Generic Name
- [18F]MNI-958
Phase 1 Test-retest Evaluation of [18F]MNI-958 PET
Phase 1
Completed
- Conditions
- Healthy VolunteersAlzheimer DiseaseProgressive Supranuclear Palsy
- Interventions
- First Posted Date
- 2018-06-04
- Last Posted Date
- 2020-02-17
- Lead Sponsor
- Invicro
- Target Recruit Count
- 16
- Registration Number
- NCT03545789
- Locations
- 🇺🇸
Invicro, New Haven, Connecticut, United States
Assessment of the Biodistribution and Safety of [18F]MNI-958 in Healthy Subjects
- First Posted Date
- 2018-03-21
- Last Posted Date
- 2018-10-22
- Lead Sponsor
- Invicro
- Target Recruit Count
- 2
- Registration Number
- NCT03472313
- Locations
- 🇺🇸
Invicro, New Haven, Connecticut, United States
Phase 0 Evaluation of [18F]MNI-958 as a Potential PET Radioligand for Imaging Tau Protein in the Brain
Early Phase 1
Completed
- Conditions
- Alzheimer DiseaseHealthy VolunteersProgressive Supranuclear Palsy
- Interventions
- First Posted Date
- 2017-02-23
- Last Posted Date
- 2019-03-25
- Lead Sponsor
- Molecular NeuroImaging
- Target Recruit Count
- 12
- Registration Number
- NCT03058965
- Locations
- 🇺🇸
Molecular NeuroImaging, LLC, New Haven, Connecticut, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath